Article
Oncology
Olivier J. van Not, Melissa M. de Meza, Alfons J. M. van den Eertwegh, John B. Haanen, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Jesper van Breeschoten, Jan-Willem B. de Groot, Geke A. P. Hospers, Rawa K. Ismail, Ellen Kapiteijn, Djura Piersma, Roos S. van Rijn, Marion A. M. Stevense-den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Han J. Bonenkamp, Marye J. Boers-Sonderen, Willeke A. M. Blokx, Michel W. J. M. Wouters, Karijn P. M. Suijkerbuijk
Summary: This study reveals the lower effectiveness of immune checkpoint inhibitors in patients with acral melanoma compared to cutaneous melanoma, with lower response rates, progression-free survival, and overall survival.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Richard J. Straker, Katharine Krupp, Cimarron E. Sharon, Alexandra S. Thaler, Nicholas J. Kelly, Emily Y. Chu, David E. Elder, Xiaowei Xu, John T. Miura, Giorgos C. Karakousis
Summary: The study investigated the prognostic impact of primary tumor-infiltrating lymphocytes (TILs) in melanoma patients, showing associations with regression rates, histology, and sentinel lymph node positivity. However, no significant associations were found with disease-specific survival. The presence of brisk TILs may be associated with an advantage in recurrence-free survival, but further studies are needed to confirm this relationship.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Jan C. Brase, Robert F. H. Walter, Alexander Savchenko, Daniel Gusenleitner, James Garrett, Tobias Schimming, Renata Varaljai, Deborah Castelletti, Ju Kim, Naveen Dakappagari, Ken Schultz, Caroline Robert, Georgina Long, Paul D. Nathan, Antoni Ribas, Keith T. Flaherty, Boguslawa Karaszewska, Jacob Schachter, Antje Sucker, Kurt W. Schmid, Lisa Zimmer, Elisabeth Livingstone, Eduard Gasal, Dirk Schadendorf, Alexander Roesch
Summary: Although patients with unresectable or metastatic melanoma can experience long-term survival with targeted therapies, resistance is common and pretherapeutic biomarkers are lacking. A study on previously untreated BRAF V600-mutant melanoma patients treated with dabrafenib plus trametinib found that baseline cell-cycle gene expression signature and T-cell/B-cell gene signatures were associated with clinical outcomes, highlighting the potential predictive role of B cells in treatment response. Further validation in larger patient cohorts is needed to confirm these findings.
CLINICAL CANCER RESEARCH
(2021)
Article
Medicine, General & Internal
Monique K. van der Kooij, Karijn P. M. Suijkerbuijk, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Marye J. Boers-Sonderen, Jesper van Breeschoten, Alfonsus J. M. van den Eertwegh, Jan Willem B. de Groot, John B. A. G. Haanen, Geke A. P. Hospers, Djura Piersma, Rozemarijn S. van Rijn, Albert J. Ten Tije, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Michiel C. T. van Zeijl, Michel W. J. M. Wouters, Olaf M. Dekkers, Ellen Kapiteijn
Summary: The safety and efficacy of immune checkpoint inhibition (ICI) in patients with advanced melanoma with and without preexisting autoimmune disease (AID) were similar, with comparable rates of severe adverse events and treatment response. However, patients with preexisting inflammatory bowel disease (IBD) were more prone to severe colitis and toxicity requiring early discontinuation of treatment, necessitating close monitoring.
ANNALS OF INTERNAL MEDICINE
(2021)
Article
Multidisciplinary Sciences
Rodabe N. Amaria, Michael Postow, Elizabeth M. Burton, Michael T. Tezlaff, Merrick Ross, Carlos Torres-Cabala, Isabella C. Glitza, Fei Duan, Denai R. Milton, Klaus Busam, Lauren Simpson, Jennifer L. McQuade, Michael K. Wong, Jeffrey E. Gershenwald, Jeffrey E. Lee, Ryan P. Goepfert, Emily Z. Keung, Sarah B. Fisher, Allison Betof-Warner, Alexander N. Shoushtari, Margaret Callahan, Daniel Coit, Edmund K. Bartlett, Danielle Bello, Parisa Momtaz, Courtney Nicholas, Aidi Gu, Xuejun Zhang, Brinda Rao Korivi, Madhavi Patnana, Sapna P. Patel, Adi Diab, Anthony Lucci, Victor G. Prieto, Michael A. Davies, James P. Allison, Padmanee Sharma, Jennifer A. Wargo, Charlotte Ariyan, Hussein A. Tawbi
Summary: The combination of Relatlimab and nivolumab improves progression-free survival and has a high pathologic complete response rate in patients with advanced melanoma. This new immunotherapy regimen shows favorable safety compared to other combination immunotherapy regimens.
Article
Dermatology
Richard J. Straker, Cimarron E. Sharon, Emily Y. Chu, John T. Miura, Michael E. Ming, Giorgos C. Karakousis
Summary: This study found that a positive result on sentinel lymph node biopsy was associated with reduced 5-year disease-specific survival in patients with clinical stage IIB/C cutaneous melanoma.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Review
Immunology
Kimberly Loo, James W. Smithy, Michael A. Postow, Allison Betof Warner
Summary: This review aims to explore the long-term survival of melanoma patients treated with immune checkpoint blockade (ICB) therapy and identify prognostic and predictive factors. The review also discusses the use of ICB combinations, retreatment with ICB, and patterns of ICB resistance based on sites of disease.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Filip Tichanek, Asta Foersti, Akseli Hemminki, Otto Hemminki, Kari Hemminki
Summary: This study analysed the survival rates of melanoma in Denmark, Finland, Norway, and Sweden from 1971 to 2020. The results showed a significant increase in survival rates over the past few decades, which could be attributed to the population's awareness of sun protection and early detection, as well as the use of novel targeted therapies and immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Evan D. Bander, Melissa Yuan, Joseph A. Carnevale, Anne S. Reiner, Katherine S. Panageas, Michael A. Postow, Viviane Tabar, Nelson S. Moss
Summary: Breakthroughs in targeted and immunotherapies have significantly improved the prognosis and overall survival of patients with melanoma brain metastasis in recent years. Factors such as serum lactate dehydrogenase levels and the presence of extracranial disease are associated with worse prognosis.
Article
Oncology
Anna Crispo, Maria Teresa Corradin, Erika Giulioni, Antonella Vecchiato, Paolo Del Fiore, Paola Queirolo, Francesco Spagnolo, Vito Vanella, Corrado Caraco, Giulio Tosti, Elisabetta Pennacchioli, Giuseppe Giudice, Eleonora Nacchiero, Pietro Quaglino, Simone Ribero, Monica Giordano, Desire Marussi, Stefania Barruscotti, Michele Guida, Vincenzo De Giorgi, Marcella Occelli, Federica Grosso, Giuseppe Cairo, Alessandro Gatti, Daniela Massa, Laura Atzori, Nicola Calvani, Tommaso Fabrizio, Giuseppe Mastrangelo, Federica Toffolutti, Egidio Celentano, Mario Budroni, Sara Gandini, Carlo Riccardo Rossi, Alessandro Testori, Giuseppe Palmieri, Paolo A. Ascierto
Summary: This study investigated the types of oncological treatments for advanced CM in Italian centers, and found that immunotherapy showed significant improvement in survival compared to other therapies. Specifically, nivolumab/pembrolizumab in combination with ipilimumab and BRAFi+MEKi were identified as the most effective therapies in improving survival in real-world populations.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Tina J. Hieken, Daniel L. Price, Mara A. Piltin, Heidi J. Turner, Matthew S. Block
Summary: The study aimed to assess the impact of neoadjuvant systemic therapies (NST) on the technical aspects of operation for resectable stage III melanoma. Surgeon surveys were conducted to capture key impressions before and after NST, revealing that while many operations were considered more difficult than usual therapeutic lymphadenectomy, surgeries following NST were often perceived as easier compared to baseline impressions. This highlights the potential benefits of engaging surgical oncologists in structured assessments across clinical trials to analyze the effect of NSTs on lymphadenectomy.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Immunology
Dan Moldoveanu, LeeAnn Ramsay, Mathieu Lajoie, Luke Anderson-Trocme, Marine Lingrand, Diana Berry, Lucas J. M. Perus, Yuhong Wei, Cleber Moraes, Rached Alkallas, Shivshankari Rajkumar, Dongmei Zuo, Matthew Dankner, Eric Hongbo Xu, Nicholas R. Bertos, Hamed S. Najafabadi, Simon Gravel, Santiago Costantino, Martin J. Richer, Amanda W. Lund, Sonia V. Del Rincon, Alan Spatz, Wilson H. Miller, Rahima Jamal, Rejean Lapointe, Anne-Marie Mes-Masson, Simon Turcotte, Kevin Petrecca, Sinziana Dumitra, Ari-Nareg Meguerditchian, Keith Richardson, Francine Tremblay, Beatrice Wang, May Chergui, Marie-Christine Guiot, Kevin Watters, John Stagg, Daniela F. Quail, Catalin Mihalcioiu, Sarkis Meterissian, Ian R. Watson
Summary: Melanoma is an immunogenic cancer that shows a high response rate to immune checkpoint inhibitors. By utilizing multiplexed single-cell technology, it has been found that the abundance of antigen-experienced cytotoxic T cells and the proximity between these T cells and melanoma cells are associated with positive response to treatment.
SCIENCE IMMUNOLOGY
(2022)
Article
Oncology
Maryam Pourmaleki, Caitlin J. Jones, Charlotte E. Ariyan, Zheng Zeng, Mono Pirun, Daniel A. Navarrete, Yanyun Li, Mianlei Zhang, Subhiksha Nandakumar, Carl Campos, Saad Nadeem, David S. Klimstra, Claire F. Temple-Oberle, Thomas Brenn, Evan J. Lipson, Kara M. Schenk, Julie E. Stein, Janis M. Taube, Michael G. White, Raymond Traweek, Jennifer A. Wargo, John M. Kirkwood, Billel Gasmi, Stephanie L. Goff, Alex D. Corwin, Elizabeth McDonough, Fiona Ginty, Margaret K. Callahan, Andrea Schietinger, Nicholas D. Socci, Ingo K. Mellinghoff, Travis J. Hollmann
Summary: Our study reveals the importance of intact tumor-cell antigen presentation and the role of exhausted CD8(+) T cells in IL2 therapy for melanoma.
CANCER IMMUNOLOGY RESEARCH
(2022)
Article
Immunology
Irene L. M. Reijers, Disha Rao, Judith M. Versluis, Alexander M. Menzies, Petros Dimitriadis, Michel W. Wouters, Andrew J. Spillane, Willem M. C. Klop, Annegien Broeks, Linda J. W. Bosch, Marta Lopez-Yurda, Winan J. van Houdt, Robert V. Rawson, Lindsay G. Grijpink-Ongering, Maria Gonzalez, Sten Cornelissen, Jasper Bouwman, Joyce Sanders, Elsemieke Plasmeijer, Yannick S. Elshot, Richard A. Scolyer, Bart A. van de Wiel, Daniel S. Peeper, Alexander C. J. van Akkooi, Georgina V. Long, Christian U. Blank
Summary: The baseline IFN-gamma signature can be used to select patients who can benefit from anti-PD-1 monotherapy in the DONIMI trial. However, the addition of domatinostat, a class I HDAC inhibitor, does not provide additional benefits in patients receiving neoadjuvant anti-PD-1 +/- anti-CTLA-4. Neoadjuvant ipilimumab + nivolumab shows high pathologic response rates in stage III melanoma, but patients with low intra-tumoral IFN-gamma signatures are less likely to benefit.
JOURNAL OF EXPERIMENTAL MEDICINE
(2023)
Article
Oncology
Adriana M. Kahn, Curtis J. Perry, Katrina Etts, Harriet Kluger, Mario Sznol
Summary: The study retrospectively analyzed patients with metastatic melanoma who received combined BRAF/MEK inhibitors after progression on previous immunotherapy, and found that age, ECOG-PS score, and bone metastasis were clinical variables associated with overall survival.